| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 22 | 2025 | 670 | 2.190 |
Why?
|
| Cerebral Hemorrhage | 11 | 2022 | 96 | 1.210 |
Why?
|
| Deep Brain Stimulation | 7 | 2022 | 36 | 1.110 |
Why?
|
| Fragile X Syndrome | 5 | 2020 | 188 | 0.930 |
Why?
|
| Female | 63 | 2025 | 15213 | 0.810 |
Why?
|
| Male | 61 | 2025 | 14772 | 0.810 |
Why?
|
| Humans | 76 | 2025 | 27074 | 0.720 |
Why?
|
| Stroke | 6 | 2018 | 261 | 0.720 |
Why?
|
| Intracranial Aneurysm | 4 | 2014 | 41 | 0.720 |
Why?
|
| Aged | 45 | 2025 | 8997 | 0.690 |
Why?
|
| Safety-net Providers | 1 | 2019 | 7 | 0.640 |
Why?
|
| Hospitals, Public | 1 | 2019 | 27 | 0.640 |
Why?
|
| Middle Aged | 40 | 2025 | 8923 | 0.630 |
Why?
|
| Sarcoidosis | 1 | 2019 | 14 | 0.620 |
Why?
|
| Central Nervous System Diseases | 1 | 2019 | 17 | 0.620 |
Why?
|
| Aneurysm, Ruptured | 2 | 2014 | 15 | 0.560 |
Why?
|
| Hallucinations | 3 | 2011 | 42 | 0.540 |
Why?
|
| Subthalamic Nucleus | 4 | 2022 | 19 | 0.540 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 5 | 2022 | 89 | 0.510 |
Why?
|
| Retrospective Studies | 23 | 2021 | 3538 | 0.490 |
Why?
|
| Thrombolytic Therapy | 3 | 2016 | 48 | 0.480 |
Why?
|
| Self-Help Groups | 1 | 2014 | 7 | 0.470 |
Why?
|
| Severity of Illness Index | 10 | 2020 | 879 | 0.470 |
Why?
|
| Fibrinolytic Agents | 3 | 2011 | 59 | 0.470 |
Why?
|
| Length of Stay | 6 | 2018 | 313 | 0.470 |
Why?
|
| Ataxia | 3 | 2020 | 76 | 0.460 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2016 | 30 | 0.460 |
Why?
|
| Cholesterol | 1 | 2014 | 64 | 0.460 |
Why?
|
| Thrombectomy | 3 | 2021 | 33 | 0.450 |
Why?
|
| Tremor | 3 | 2020 | 104 | 0.450 |
Why?
|
| Adult | 23 | 2021 | 7831 | 0.440 |
Why?
|
| Social Media | 1 | 2014 | 52 | 0.430 |
Why?
|
| Brain Ischemia | 3 | 2021 | 63 | 0.420 |
Why?
|
| Seizures | 3 | 2019 | 67 | 0.410 |
Why?
|
| Biostatistics | 1 | 2012 | 5 | 0.410 |
Why?
|
| Glucosylceramidase | 3 | 2022 | 15 | 0.410 |
Why?
|
| Bayes Theorem | 1 | 2012 | 42 | 0.400 |
Why?
|
| Heart Transplantation | 1 | 2012 | 30 | 0.400 |
Why?
|
| Risk Factors | 14 | 2021 | 2302 | 0.400 |
Why?
|
| Hospital Mortality | 4 | 2017 | 130 | 0.380 |
Why?
|
| Quality of Life | 6 | 2025 | 629 | 0.380 |
Why?
|
| Health Facilities | 1 | 2011 | 23 | 0.380 |
Why?
|
| Databases, Factual | 4 | 2022 | 347 | 0.370 |
Why?
|
| Hematoma, Subdural, Acute | 3 | 2017 | 7 | 0.370 |
Why?
|
| Health Status Disparities | 2 | 2025 | 75 | 0.360 |
Why?
|
| Postoperative Complications | 4 | 2018 | 916 | 0.360 |
Why?
|
| Young Adult | 10 | 2021 | 1994 | 0.350 |
Why?
|
| Cognition Disorders | 4 | 2021 | 985 | 0.330 |
Why?
|
| Accidental Falls | 3 | 2020 | 110 | 0.330 |
Why?
|
| Parkinsonian Disorders | 3 | 2022 | 225 | 0.320 |
Why?
|
| Gait | 4 | 2020 | 412 | 0.320 |
Why?
|
| Diet, Ketogenic | 2 | 2019 | 4 | 0.310 |
Why?
|
| Treatment Outcome | 15 | 2021 | 3485 | 0.310 |
Why?
|
| Drug Resistant Epilepsy | 2 | 2019 | 10 | 0.310 |
Why?
|
| Disease Progression | 1 | 2011 | 673 | 0.310 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 4777 | 0.300 |
Why?
|
| Brain | 5 | 2021 | 1649 | 0.290 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2020 | 133 | 0.280 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 474 | 0.280 |
Why?
|
| Neuropsychological Tests | 5 | 2022 | 1196 | 0.260 |
Why?
|
| Prospective Studies | 11 | 2025 | 1778 | 0.260 |
Why?
|
| Time Factors | 8 | 2020 | 1433 | 0.260 |
Why?
|
| Mentors | 2 | 2023 | 36 | 0.260 |
Why?
|
| Patient Transfer | 2 | 2017 | 21 | 0.260 |
Why?
|
| Illinois | 3 | 2019 | 250 | 0.260 |
Why?
|
| Caregivers | 3 | 2023 | 197 | 0.250 |
Why?
|
| Biopsy | 2 | 2019 | 201 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2022 | 1112 | 0.240 |
Why?
|
| Trinucleotide Repeat Expansion | 3 | 2020 | 45 | 0.240 |
Why?
|
| Mutation | 3 | 2022 | 348 | 0.230 |
Why?
|
| Hospitalization | 3 | 2020 | 300 | 0.230 |
Why?
|
| Fragile X Mental Retardation Protein | 3 | 2020 | 115 | 0.230 |
Why?
|
| Hematoma, Subdural | 2 | 2015 | 6 | 0.230 |
Why?
|
| Heterozygote | 2 | 2022 | 100 | 0.220 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 88 | 0.220 |
Why?
|
| Prognosis | 4 | 2020 | 785 | 0.220 |
Why?
|
| Attention | 3 | 2020 | 124 | 0.210 |
Why?
|
| Psychometrics | 2 | 2014 | 220 | 0.210 |
Why?
|
| Child, Preschool | 4 | 2021 | 641 | 0.210 |
Why?
|
| Postural Balance | 2 | 2021 | 117 | 0.210 |
Why?
|
| Spinal Fusion | 3 | 2018 | 457 | 0.200 |
Why?
|
| Case-Control Studies | 8 | 2020 | 587 | 0.200 |
Why?
|
| Walking Speed | 2 | 2020 | 41 | 0.200 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2011 | 42 | 0.200 |
Why?
|
| Phenotype | 2 | 2025 | 312 | 0.200 |
Why?
|
| Homebound Persons | 1 | 2022 | 6 | 0.200 |
Why?
|
| Physical Therapists | 1 | 2022 | 4 | 0.200 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2022 | 17 | 0.200 |
Why?
|
| Cerebral Amyloid Angiopathy | 3 | 2019 | 111 | 0.200 |
Why?
|
| Executive Function | 3 | 2018 | 111 | 0.200 |
Why?
|
| Psychomotor Performance | 2 | 2020 | 205 | 0.200 |
Why?
|
| Blood Pressure Determination | 1 | 2022 | 14 | 0.200 |
Why?
|
| Lewy Body Disease | 1 | 2023 | 97 | 0.200 |
Why?
|
| Arterial Pressure | 1 | 2022 | 11 | 0.200 |
Why?
|
| Mentoring | 1 | 2022 | 27 | 0.200 |
Why?
|
| Cognitive Dysfunction | 4 | 2020 | 1061 | 0.190 |
Why?
|
| Weather | 2 | 2019 | 11 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2018 | 683 | 0.190 |
Why?
|
| Pilot Projects | 5 | 2023 | 420 | 0.190 |
Why?
|
| Longitudinal Studies | 6 | 2021 | 1368 | 0.190 |
Why?
|
| Medical Futility | 1 | 2021 | 5 | 0.180 |
Why?
|
| Leukoaraiosis | 1 | 2021 | 9 | 0.180 |
Why?
|
| Adolescent | 8 | 2021 | 2172 | 0.180 |
Why?
|
| Multidetector Computed Tomography | 1 | 2021 | 12 | 0.180 |
Why?
|
| Cognition | 4 | 2022 | 1339 | 0.180 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 158 | 0.180 |
Why?
|
| Martial Arts | 1 | 2020 | 4 | 0.180 |
Why?
|
| Hyperglycemia | 1 | 2020 | 29 | 0.170 |
Why?
|
| Telemedicine | 1 | 2022 | 97 | 0.170 |
Why?
|
| Sleep Wake Disorders | 2 | 2013 | 123 | 0.170 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.170 |
Why?
|
| Blood Glucose | 1 | 2020 | 104 | 0.170 |
Why?
|
| Decompression, Surgical | 2 | 2018 | 125 | 0.170 |
Why?
|
| Nootropic Agents | 1 | 2020 | 14 | 0.170 |
Why?
|
| Depression | 2 | 2016 | 444 | 0.160 |
Why?
|
| Odds Ratio | 4 | 2017 | 270 | 0.160 |
Why?
|
| Arm | 1 | 2020 | 83 | 0.160 |
Why?
|
| Movement Disorders | 1 | 2020 | 66 | 0.160 |
Why?
|
| Huntington Disease | 1 | 2020 | 48 | 0.160 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 27 | 0.160 |
Why?
|
| Child | 5 | 2022 | 1295 | 0.160 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2019 | 8 | 0.160 |
Why?
|
| Microelectrodes | 1 | 2018 | 18 | 0.150 |
Why?
|
| Electrodes, Implanted | 1 | 2018 | 21 | 0.150 |
Why?
|
| Middle Cerebral Artery | 1 | 2018 | 7 | 0.150 |
Why?
|
| Walking | 1 | 2020 | 253 | 0.150 |
Why?
|
| Carotid Artery, Internal | 1 | 2018 | 6 | 0.150 |
Why?
|
| Population Surveillance | 1 | 2019 | 115 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 115 | 0.150 |
Why?
|
| Tertiary Care Centers | 2 | 2015 | 68 | 0.150 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2017 | 5 | 0.150 |
Why?
|
| Lumbosacral Region | 1 | 2018 | 58 | 0.140 |
Why?
|
| Corpus Striatum | 1 | 2018 | 65 | 0.140 |
Why?
|
| Disability Evaluation | 5 | 2021 | 264 | 0.140 |
Why?
|
| Dopamine | 1 | 2018 | 82 | 0.140 |
Why?
|
| Cerebral Ventriculitis | 1 | 2017 | 1 | 0.140 |
Why?
|
| Ventriculostomy | 1 | 2017 | 5 | 0.140 |
Why?
|
| Meningitis, Bacterial | 1 | 2017 | 4 | 0.140 |
Why?
|
| Meningitis, Aseptic | 1 | 2017 | 4 | 0.140 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2017 | 10 | 0.140 |
Why?
|
| Lactic Acid | 1 | 2017 | 7 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2018 | 116 | 0.130 |
Why?
|
| Fever | 1 | 2017 | 34 | 0.130 |
Why?
|
| Antidepressive Agents | 1 | 2017 | 97 | 0.130 |
Why?
|
| Unemployment | 1 | 2016 | 2 | 0.130 |
Why?
|
| Epilepsy | 1 | 2017 | 60 | 0.130 |
Why?
|
| Depressive Disorder | 1 | 2017 | 177 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 171 | 0.120 |
Why?
|
| Substantia Nigra | 1 | 2016 | 120 | 0.120 |
Why?
|
| Diskectomy | 1 | 2018 | 179 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 117 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2018 | 1890 | 0.120 |
Why?
|
| Anxiety | 1 | 2016 | 156 | 0.120 |
Why?
|
| alpha-Synuclein | 1 | 2016 | 130 | 0.120 |
Why?
|
| Cervical Vertebrae | 1 | 2018 | 281 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 38 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2015 | 45 | 0.110 |
Why?
|
| Logistic Models | 5 | 2017 | 395 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 104 | 0.110 |
Why?
|
| Vascular Access Devices | 1 | 2013 | 4 | 0.110 |
Why?
|
| Lumbar Vertebrae | 1 | 2018 | 383 | 0.110 |
Why?
|
| Neoplasms | 1 | 2016 | 237 | 0.110 |
Why?
|
| Cerebral Arteries | 1 | 2013 | 25 | 0.110 |
Why?
|
| Cerebral Angiography | 1 | 2013 | 33 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2013 | 65 | 0.100 |
Why?
|
| Biomarkers | 3 | 2022 | 562 | 0.100 |
Why?
|
| Stochastic Processes | 1 | 2012 | 12 | 0.100 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2012 | 6 | 0.100 |
Why?
|
| House Calls | 2 | 2022 | 15 | 0.100 |
Why?
|
| Graft Rejection | 1 | 2012 | 68 | 0.100 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2012 | 22 | 0.100 |
Why?
|
| Menopause, Premature | 1 | 2012 | 7 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2012 | 127 | 0.100 |
Why?
|
| Temporal Lobe | 1 | 2012 | 83 | 0.100 |
Why?
|
| Health Facility Size | 1 | 2011 | 2 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 1144 | 0.100 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 25 | 0.100 |
Why?
|
| International Classification of Diseases | 1 | 2011 | 13 | 0.100 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 133 | 0.100 |
Why?
|
| Radiography | 4 | 2015 | 619 | 0.090 |
Why?
|
| Drug Utilization | 1 | 2011 | 22 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2011 | 94 | 0.090 |
Why?
|
| Certification | 1 | 2011 | 24 | 0.090 |
Why?
|
| Ischemic Attack, Transient | 1 | 2011 | 18 | 0.090 |
Why?
|
| Incidence | 3 | 2019 | 759 | 0.090 |
Why?
|
| Cholecystokinin | 1 | 2011 | 5 | 0.090 |
Why?
|
| Mental Status Schedule | 1 | 2011 | 90 | 0.090 |
Why?
|
| Communication Disorders | 1 | 2011 | 4 | 0.090 |
Why?
|
| Circle of Willis | 1 | 2011 | 5 | 0.090 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2010 | 3 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2011 | 88 | 0.090 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2010 | 19 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2022 | 220 | 0.090 |
Why?
|
| Chicago | 3 | 2021 | 949 | 0.090 |
Why?
|
| Medication Errors | 1 | 2010 | 12 | 0.090 |
Why?
|
| Vitamin B Deficiency | 1 | 2010 | 1 | 0.090 |
Why?
|
| Vitamin B Complex | 1 | 2010 | 6 | 0.090 |
Why?
|
| Reference Values | 2 | 2021 | 186 | 0.090 |
Why?
|
| Walk Test | 2 | 2020 | 10 | 0.080 |
Why?
|
| Prevalence | 4 | 2013 | 443 | 0.080 |
Why?
|
| Sleep | 1 | 2013 | 328 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 278 | 0.080 |
Why?
|
| Atmospheric Pressure | 2 | 2019 | 6 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2012 | 235 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 381 | 0.080 |
Why?
|
| Brain Infarction | 1 | 2009 | 75 | 0.080 |
Why?
|
| United States | 3 | 2025 | 2035 | 0.080 |
Why?
|
| Hypertension | 3 | 2018 | 192 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2022 | 482 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2017 | 624 | 0.070 |
Why?
|
| Age Factors | 3 | 2017 | 766 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 1792 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 329 | 0.060 |
Why?
|
| Alleles | 2 | 2020 | 216 | 0.060 |
Why?
|
| Range of Motion, Articular | 2 | 2020 | 708 | 0.060 |
Why?
|
| False Positive Reactions | 2 | 2017 | 34 | 0.060 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 22 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 139 | 0.050 |
Why?
|
| Comorbidity | 2 | 2017 | 481 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2018 | 295 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 31 | 0.050 |
Why?
|
| Prebiotics | 1 | 2023 | 22 | 0.050 |
Why?
|
| Learning | 1 | 2023 | 71 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2014 | 57 | 0.050 |
Why?
|
| Survivors | 2 | 2015 | 70 | 0.050 |
Why?
|
| Feces | 1 | 2023 | 103 | 0.050 |
Why?
|
| Radial Artery | 1 | 2022 | 8 | 0.050 |
Why?
|
| Blindness | 1 | 2022 | 8 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 2109 | 0.050 |
Why?
|
| Atrophy | 1 | 2021 | 91 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 44 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 144 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2022 | 195 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 4 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 272 | 0.040 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 19 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 64 | 0.040 |
Why?
|
| Foot | 1 | 2020 | 44 | 0.040 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2019 | 3 | 0.040 |
Why?
|
| Neurosurgeons | 1 | 2018 | 6 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2018 | 19 | 0.040 |
Why?
|
| Temperature | 1 | 2018 | 63 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 43 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2018 | 56 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 38 | 0.040 |
Why?
|
| Independent Living | 1 | 2021 | 322 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2020 | 644 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 49 | 0.040 |
Why?
|
| Putamen | 1 | 2018 | 19 | 0.040 |
Why?
|
| Cameroon | 1 | 2017 | 1 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 11 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 111 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 133 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 54 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 34 | 0.040 |
Why?
|
| Motor Activity | 1 | 2020 | 323 | 0.030 |
Why?
|
| Body Temperature Regulation | 1 | 2017 | 18 | 0.030 |
Why?
|
| Spinal Puncture | 1 | 2017 | 25 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 44 | 0.030 |
Why?
|
| Heart Failure | 1 | 2018 | 151 | 0.030 |
Why?
|
| Olfactory Bulb | 1 | 2016 | 17 | 0.030 |
Why?
|
| Locus Coeruleus | 1 | 2016 | 21 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 125 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2017 | 56 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2017 | 77 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 189 | 0.030 |
Why?
|
| Inpatients | 1 | 2017 | 125 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 293 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 406 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 8 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 310 | 0.030 |
Why?
|
| Infant | 1 | 2017 | 564 | 0.030 |
Why?
|
| Space Perception | 1 | 2014 | 22 | 0.030 |
Why?
|
| Probability | 1 | 2014 | 88 | 0.030 |
Why?
|
| Ventilator Weaning | 1 | 2015 | 34 | 0.030 |
Why?
|
| Language | 1 | 2014 | 63 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2013 | 14 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2013 | 29 | 0.030 |
Why?
|
| Troponin I | 1 | 2013 | 10 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2015 | 94 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2015 | 158 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2015 | 122 | 0.030 |
Why?
|
| Sleep Stages | 1 | 2013 | 23 | 0.030 |
Why?
|
| Memory Disorders | 1 | 2014 | 159 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2015 | 261 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2013 | 100 | 0.030 |
Why?
|
| HIV Infections | 1 | 2017 | 466 | 0.020 |
Why?
|
| Models, Economic | 1 | 2011 | 7 | 0.020 |
Why?
|
| Decision Trees | 1 | 2011 | 13 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2011 | 20 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 47 | 0.020 |
Why?
|
| Memory | 1 | 2013 | 297 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 123 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 60 | 0.020 |
Why?
|
| Social Behavior Disorders | 1 | 2011 | 5 | 0.020 |
Why?
|
| Language Disorders | 1 | 2011 | 7 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 83 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 176 | 0.020 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2010 | 2 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2010 | 6 | 0.020 |
Why?
|
| Vitamin B 6 | 1 | 2010 | 4 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 52 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 891 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 2010 | 13 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2010 | 25 | 0.020 |
Why?
|
| Folic Acid | 1 | 2010 | 21 | 0.020 |
Why?
|
| Body Weight | 1 | 2010 | 134 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 346 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 464 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 333 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 415 | 0.020 |
Why?
|